Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$16.43
+$0.03 · +0.18%
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Regular session
$16.43
+$0.03 · +0.18%
Regular session · ET · Market data may be delayed.
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Day range
Current $16.43
52-week range
Current $16.43
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
24
Expensive
Sentiment
51
Mixed
Risk
56
Elevated Risk
Momentum
75
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Day range
Current $16.43
52-week range
Current $16.43
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 69.65M USD | 84.61M USD | 73.48M USD | 65.05M USD | 85.49M USD |
| Cost of goods sold | 53.87M USD | 57.79M USD | 55.27M USD | 51.7M USD | 53.84M USD |
| Gross profit | 15.78M USD | 26.83M USD | 18.21M USD | 13.35M USD | 31.66M USD |
| Research and development | 50.26M USD | 48.91M USD | 64.78M USD | 64.91M USD | 49.31M USD |
| Selling, general, and administrative | 53.57M USD | 46.19M USD | 49.73M USD | 63.97M USD | 47.7M USD |
| Operating expenses | 103.83M USD | 95.09M USD | 114.5M USD | 128.88M USD | 97.01M USD |
| Interest income | 7.16M USD | 5.51M USD | 5.9M USD | 2.4M USD | 367K USD |
| Interest expense | 205K USD | 24K USD | 110K USD | 201K USD | 184K USD |
| Depreciation and amortization | 10.05M USD | 10.94M USD | 11.3M USD | 8.43M USD | 6.01M USD |
| Operating income | −88.06M USD | −68.27M USD | −96.29M USD | −115.53M USD | −65.35M USD |
| Net income | −81.27M USD | −81.28M USD | −108.3M USD | −113.32M USD | −65.23M USD |
Company facts updated Sep 10, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Genomic Revolution ETFARKG113.21M5.76%1.56B USD0.75%$45.655-1.40%
iShares Russell 2000 ETFIWM28.42M0.04%80.51B USD0.19%$288.3-0.81%
Vanguard Morningstar Total Stock Market ETFVTI27.12M0.00%2.3T USD0.03%$373.78-0.47%
iShares Russell 2000 Value ETFIWN10.46M0.07%14.61B USD0.24%$218.86-0.74%
Vanguard Extended Market ETFVXF10.09M0.01%93.7B USD0.05%$236.99-0.71%
iShares Biotechnology ETFIBB7.72M0.07%10.73B USD0.44%$203.04-1.19%
Dimensional - US Small Cap ETFDFAS5.52M0.04%15.36B USD0.26%$80.14-0.52%
Vanguard Russell 2000 ETFVTWO4.82M0.03%17.4B USD0.06%$116.55-0.82%ARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Value ETFIWNVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
